Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison
MAIC analysis found that fezolinetant and elinzanetant had a similar efficacy profile for reduction of VMS frequency and severity. Differences in reduction of sleep disturbances did not result in differences in QoL. Neurokinin receptor antagonists provide an alternative to HT and other non-HT options for the treatment of VMS associated with menopause.
Authors
- T. Tai (ORCID: https://orcid.org/0000-0001-9386-3988)
- Petra Stute (ORCID: https://orcid.org/0000-0002-5591-1552)
- Hua Yang (ORCID: https://orcid.org/0000-0001-5536-503X)
- Mayank Ajmera (ORCID: https://orcid.org/0000-0003-3562-8298)
- Angela Zhao (ORCID: https://orcid.org/0009-0004-5019-9094)
- Karla Martins (ORCID: https://orcid.org/0000-0002-5306-7124)
- Rossella Elena Nappi (ORCID: https://orcid.org/0000-0003-1713-6396)
- Antonia Morga (ORCID: https://orcid.org/0009-0008-6671-5056)
- Cristina I. Mureşan (ORCID: https://orcid.org/0000-0003-2301-4133)
- Jingyi Liu (ORCID: https://orcid.org/0000-0001-6251-6051)
- Colin M. Shapiro (ORCID: https://orcid.org/0000-0002-2231-0427)
Institutions
- University Hospital of Bern (CH)
- Astellas Pharma (United Kingdom) (GB)
- Astellas Pharma (Netherlands) (NL)
- Astellas Pharma (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Maturitas
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1016/j.maturitas.2025.108782
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00